>Revista de Hematología
>Year 2013, Issue 3
Zamora-Ortiz G, Morales-Floranes R, Velázquez-Sánchez-de-Cima S, García-Villaseñor A, Ruiz-Argüelles GJ
Gender as a prognostic factor for overall survival in patients auto or allografted employing the Mexican Method: A single institution experience
Rev Hematol Mex 2013; 14 (3)
PDF: 320.52 Kb.
Background: Several variables influence the prognosis of patients
after hematopoietic stem cell transplantation (HSCT), but there are
discrepancies in the results of different studies that include gender
as a prognosis factor.
Objective: To determine the role of gender as a prognostic factor
in overall survival (OS) post HSCT.
Material and methods: Retrospective study of 285 patients undergoing
HSCT between January 1993 and September 2012 in
the Clínica Ruiz de Puebla.
Results: In the period indicated, 155 allogeneic transplants were
done, 40% female and 60% male, diagnosed with acute myelogenous
leukemia (AML) in 25%, acute lymphoblastic leukemia (ALL)
in 23%, chronic mielogenous leukemia (CML) in 19%. The OS, in
women, was 38% at 131 months and 35% at 155 months, in men. In
the same period, 130 autologous transplants were performed, 48%
female and 52% male, diagnosed with multiple myeloma in 38%, ALL
in 17%, AML in 15%. The OS was 58% at 214 months in women,
and 65% at 229 months, in men. The OS was calculated according
to the Kaplan Meier method and linear regression was performed
analyzing OS with gender, age, body mass index and underlying
diagnosis basis, obtaining R2 of 0.0335. T test was performed for
gender and OS, without statistical significance.
Conclusions: In this study, which included autologous and allogeneic
transplants, regardless of age or diagnsosis, there was
no statistically significant difference in terms of gender in the OS
||Hematopoietic stem cell transplantation, survival, prognosis, sex.
Ruiz-Argüelles GJ. Whither the bone marrow transplant. Hematology 2010;15:1-3.
Miel CM, Martin PJ, Leisenring W, et al. Graft-versus-hostdisease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102: 756-762.
Bacigalupo A. Third EBMT/AMGEN workshop on reducedintensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004;33:691-696.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk. Lymphoma 2004;45:1191-1195.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Morales E. Trasplante de células progenitoras hematopoyéticas. En: Góngora-Biachi R. (editor) Hematología: Actualización 2004. México: Agrupación Mexicana para el Estudio de la Hematología, Mérida, 2004;139-148.
Ruiz-Argüelles GJ. Historia del trasplante de médula ósea en México. Rev Hematol Méx 2004;5:80-85.
Arcese W, Goldman JM, D’Arcangelo E, Schattenberg A, Nardi A, Apperley JF, et al. Outcome for patients who relapse after allogenic bone marrow transplantation for chronic myeloid leukemia. Blood FALTA;82:3211-3219.
Gahrton G, Iacobelli S, Apperley J, Bandini G, Bladé J, Boiron JM, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 2005;35:609-617.
Harvey J, Green A, Cornish J, Steward C, Cummins M, Keen L, et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplantation 2012;47:1294-1300.
Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, et al. Allogenic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009;114:2060-2067.
Locatelli F, Nölke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomnocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;:410-419.
>Revista de Hematología
>Year 2013, Issue 3